Signant Health Sees Pediatric Obesity Drug Trials Extending Into 2030s
Signant Health expects pediatric obesity drug trials to continue into the 2030s.
Related stories
CVG Reports Q3 2026 Results, Raises Revenue Outlook and Names CEO
CVG reported third-quarter results, raised its revenue outlook and narrowed its Adjusted EBITDA guidance range. It appointed David Ruppel as president and CEO and a board member.
M impact | EQUITY | Nov 02, 2026, 09:45 PM UTC
Pershing Square Reports Q3 Revenue of USD 56.6 Million
M impact | EQUITY | Nov 02, 2026, 09:36 PM UTC
California Resources Reports Third-Quarter 2026 Results
California Resources raised its quarterly dividend by 4% and reported 2% quarter-over-quarter net production growth.
M impact | EQUITY | Nov 02, 2026, 09:36 PM UTC
Cabot Corporation Reports Fourth-Quarter and Fiscal-Year 2026 Results
M impact | EQUITY | Nov 02, 2026, 09:36 PM UTC
Apple shares fall 1.79% to $332.28 in extended trading
Apple shares were down 1.79% at $332.28 in extended trading following results.
M impact | EQUITY | Nov 02, 2026, 09:36 PM UTC
Lattice Semiconductor Reports Record Q3 Revenue of $291 Million, Up 118%
Lattice Semiconductor reported third-quarter 2026 revenue of $291.0 million, up 118.3% year over year, including AMI results following its July acquisition. GAAP diluted EPS was $0
M impact | EQUITY | Nov 02, 2026, 09:36 PM UTC